A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 6
Abstract
The online version of this article (doi:10.1208/s12248-015-9815-8) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Ahmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, Thomas Zander, Lucia Nogova, Martin Kocher, Ulrich Jaehde, Jürgen Wolf, Uwe Fuhr
Keywords
Related Articles
- EP ID EP681028
- DOI 10.1208/s12248-015-9815-8
- Views 43
- Downloads 0
Bioequivalence of thyroid preparations: The final word?
Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems
Despite its apparent easy accessibility, the eye is, in fact, well protected against the absorption of foreign materials, including therapeutic agents, by the eyelids, by the tearflow, and by the permeability barriers im...
Critical Factors Influencing the In Vivo Performance of Long-acting Lipophilic Solutions—Impact on In Vitro Release Method Design
Parenteral long-acting lipophilic solutions have been used for decades and might in the future be used in the design of depots with tailored delivery characteristics. The present review highlights major factors influenci...
DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression
Receptor-binding ligands have been incorporated into DNA/polyethylenimine (PEI) complexes to enhance cell binding and cellular internalization. This study characterizes receptor-mediated uptake of DNA/PEI complexes on a...
Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates